An interventional study of Biospecimen Collection and Device Usage in Bladder Carcinoma, Breast Carcinoma and Colorectal Carcinoma, sponsored by National Cancer Institute (NCI). Recruiting at 49 sites in United States. Open to participants aged 45 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by National Cancer Institute (NCI) · Not applicable, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 67 studies in Urinary Bladder Neoplasms by National Cancer Institute (NCI) — 10 open to participants now, 23 under way, 3 of them phase 3. Urinary Bladder Neoplasms · National Cancer Institute (NCI).
Among the 67 studies in Urinary Bladder Neoplasms by National Cancer Institute (NCI), this one has the largest planned enrollment of the 56 interventional ones that give a count, is one of 4 that started in 2025, is the only one with no phase, reaches primary completion later than 17 of the 20 other live ones, and was the 66th registered.
1,803 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.
Browse Urinary Bladder Neoplasms studies →10 of the 67 studies in Urinary Bladder Neoplasms by National Cancer Institute (NCI) are open now, in 3 countries. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
National Cancer Institute (NCI) · Sites in United States, Canada
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
By country, each count listing its studies:
Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.
This study: 45 Years to 75 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
67 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 35 · Phase 3 5
First in 1994; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 24,000 is above the median of 60 across 1,299 interventional studies indexed under Urinary Bladder Neoplasms.
Median enrollment 39 across the 56 interventional studies, 800 across the 10 observational. Of the 42 that completed or were terminated, 21 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
National Cancer Institute (NCI) is the lead sponsor of 3,557 studies on the registry; 335 are open to participants now.
Of its 412 completed or terminated interventional studies of FDA-regulated products, 374 (91%) have results posted.
9 of the studies in Urinary Bladder Neoplasms by National Cancer Institute (NCI) that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04963153National Cancer Institute (NCI)Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy | 2026-12-01 |
| NCT04164082National Cancer Institute (NCI)Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer | 2026-12-09 |
| NCT03375307National Cancer Institute (NCI)Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes | 2026-12-16 |
| NCT02379429National Cancer Institute (NCI)Care of the Urothelial Cancer Patient and Prospective Procurement of Urothelial Cancer Tissue | 2027-01-01 |
| NCT03866382National Cancer Institute (NCI)Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors | 2027-02-28 |
Add all 9 to your calendar (.ics) → With an account.
Among the 67 studies in Urinary Bladder Neoplasms by National Cancer Institute (NCI), from their registry updates:
This tab as a report to print or save as PDF → With an account.
The Vanguard Study is a feasibility study to explore several aspects of evaluating multi-cancer detection (MCD) tests in a future definitive randomized controlled trial. An MCD test measures markers in the blood in order to screen for multiple cancers simultaneously. There is a need to understand how MCDs may work as cancer screening tools. The goal of cancer screening is to reduce the burden of cancer by identifying cancers before they show symptoms or signs, when treatment is likely to be most effective. In this study, adults aged 45-75 without cancer will be randomly assigned to one of 3 groups: 2 separate MCD test groups or a control group. These two MCD tests will not be compared to each other but will be compared to cancers detected in the control group. This study will provide early information on how well MCD tests perform as cancer screening tools. It will also help researchers understand how patients and their doctors make decisions about their care when the MCD test result comes back as normal (negative) or abnormal (positive).
PRIMARY OBJECTIVES:
I. Assess the feasibility of recruitment and adherence to protocol-required baseline and follow-up data and blood collection.
II. Assess the feasibility of achieving representative enrollment across participating recruitment sites.
SECONDARY OBJECTIVES:
I. To assess the impact of participant blinding on willingness to participate, adherence to protocol required baseline and follow-up data, blood collection, and rates of standard of care screening.
II. To determine the timeliness of returning test results to participants. III. To understand the factors contributing to lack of diagnostic resolution of an abnormal MCD test.
IV. To examine the effects of participant characteristics, including cancer risk factors and social determinants of health, on all aspects of feasibility.
V. To estimate the proportion of participants receiving an MCD test outside of the trial.
VI. To assess the feasibility of a staggered introduction of the second MCD assay intervention arm.
VII. To estimate the proportion of abnormal MCD tests that are diagnostically resolved, and the time to resolution.
VIII. To compare the proportion of participants who receive standard of care screening during follow-up between the intervention and control arms.
IX. To assess the accuracy of tissue of origin prediction for each MCD assay. X. To estimate the incidence of complications related to diagnostic evaluation of an abnormal MCD test result.
XI. To assess the effect of an abnormal MCD test and diagnostic workup on anxiety and cancer worry.
XII. To evaluate the clinical diagnostic performance of the MCD assays.
EXPLORATORY OBJECTIVES:
I. To estimate rates of late-stage cancer, and the distribution of cancer stage.
II. To estimate assay-targeted cancer-specific mortality of each MCD assay, all cancer-specific mortality, and all-cause mortality.
III. To develop preliminary estimates of the total and incremental budget impact of MCD testing compared to current screening practice from the payor perspective.
IV. To develop preliminary estimates of the economic burden and impact of MCD testing from the participant perspective.
V. To assess the willingness of participants who reported military service to describe military-related environmental exposures by completing the Military Exposure Questionnaire.
OUTLINE: Participants are randomized to 1 of 3 arms.
ARM I: Participants undergo blood collection for Shield MCD testing at enrollment and after one year on study. Participants at unblinded sites are provided results of tests and those with abnormal results follow up with their clinician for additional testing. Participants at blinded sites are provided abnormal results and will follow up with their clinician for additional testing.
ARM II: Participants undergo blood collection for Avantect MCD testing at enrollment and after one year on study. Participants at unblinded sites are provided results of tests and those with abnormal results follow up with their clinician for additional testing. Participants at blinded sites are provided abnormal results and will follow up with their clinician for additional testing.
ARM III (Control): Participants undergo blood collection at enrollment and after one year on study.
After completion of study intervention, participants are followed passively up to 10 years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Understand and be able to complete and participant questionnaires in English, Spanish, or Arabic
Exclusion Criteria:
Solid malignant tumor or blood cancer diagnosis, with or without treatment, within the last 5 years
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants undergo blood collection for Shield MCD testing at enrollment and after one year on study. Participants at unblinded sites are provided results of tests and those with abnormal results follow up with their clinician for additional testing. Participants at blinded sites are provided abnormal results and will follow up with their clinician for additional testing.
Procedure: Biospecimen Collection · Device: Device Usage · Other: Electronic Health Record Review · Procedure: Multi-Cancer Early Detection Test · Other: Questionnaire Administration
Participants undergo blood collection for Avantect MCD testing at enrollment and after one year on study. Participants at unblinded sites are provided results of tests and those with abnormal results follow up with their clinician for additional testing. Participants at blinded sites are provided abnormal results and will follow up with their clinician for additional testing.
Procedure: Biospecimen Collection · Device: Device Usage · Other: Electronic Health Record Review · Procedure: Multi-Cancer Early Detection Test · Other: Questionnaire Administration
Participants undergo blood collection at enrollment and after one year on study.
Procedure: Biospecimen Collection · Other: Electronic Health Record Review · Other: Questionnaire Administration
Undergo blood collection
Also known as: Biological Sample Collection, Biospecimen Collected, Sample Collection, Specimen Collection
Evaluation of MCD tests
Also known as: Usage of Device
Obtain health data
Undergo Shield MCD test
Also known as: Early detection (MSED) test, MCD Assay, MCD Test, MCED Assay, MCED Test, MSED Test, Multi Cancer Detection Assay, Multi Cancer Detection Test, Multi Cancer Early Detection Assay, Multi Cancer Early Detection Test, Multi-cancer detection (MCD) test, Multi-Cancer Detection Assay, Multi-Cancer Detection Test, Multi-cancer early detection (MCED) test, Multi-Cancer Early Detection Assay, Multi-cancer screening, Multi-cancer screening test
Undergo Avantect MCD test
Also known as: Early detection (MSED) test, MCD Assay, MCD Test, MCED Assay, MCED Test, MSED Test, Multi Cancer Detection Assay, Multi Cancer Detection Test, Multi Cancer Early Detection Assay, Multi Cancer Early Detection Test, Multi-cancer detection (MCD) test, Multi-Cancer Detection Assay, Multi-Cancer Detection Test, Multi-cancer early detection (MCED) test, Multi-Cancer Early Detection Assay, Multi-cancer screening, Multi-cancer screening test
Study specific questionnaires
Feasibility of enrollment onto study
The number of participants enrolled into the study compared to trial goals.
Time frame: At time of randomization
Proportion of participants who complete baseline and follow-up questionnaires within 60 days of receipt
The proportion of participants who are complete questionnaires and timing of completion.
Time frame: Up to 3 years
Proportion of participants who provide the required blood sample for year 1 for Multi-Cancer Detection (MCD) testing within 90 days of recommended time point
The proportion of participants who have a second blood draw and the timing of the blood draw.
Time frame: Up to 2 years
Proportion of participants considered lost to follow-up within 2 years of randomization
The proportion of participants who do not complete study procedures and are not able to be contacted.
Time frame: Up to 2 years
Representative enrollment
Meeting or exceeding the trial enrollment goals on a population basis.
Time frame: Up to 2 years
Staggered start of intervention arm 2
Advantages and challenges arising from trial activation with one intervention arm and later addition of a second intervention arm.
Time frame: Up to 1 year
Impact of participant blinding
Comparisons between blinded and unblinded sites on participation rates, adherence to protocol-required questionnaires and blood collection, and participation in standard of care screening.
Time frame: Up to 2 years
Timely return of MCD test result
The time from receipt of the MCD test result at the Statistics and Data Management Center to the time of receipt of the MCD test result at the ACCESS Hub. The time from receipt of MCD test result at the ACCESS Hub to the time of participant receipt of the MCD test result.
Time frame: Up to 2 years
Factors contributing to lack of diagnostic resolution of an abnormal MCD test
Factors that contribute to the inability to determine if a participant has a cancer or rule out cancer.
Time frame: Up to 2 years
Contamination
Estimated as the number of participants receiving MCD testing outside the trial.
Time frame: Up to 3 years
Effects of participant characteristics
Feasibility outcomes will be reported by participant demographics and cancer risk factors.
Time frame: Up to 2 years
Diagnostic resolution following an abnormal MCD test result
The proportion of participants with a "Cancer diagnosis" or "No cancer diagnosis" among all participants with an abnormal MCD test result will be reported for each MCD test. The fraction of "Unresolved" will also be reported.
Time frame: Up to 12 years
Time to diagnostic resolution
Time frame: From date of Hub receipt of abnormal MCD test result to date of provider-reported diagnostic resolution (Cancer diagnosis or No cancer diagnosis), up to 12 months
Participation in standard of care screening
The proportion of participants that receive standard of care cancer screening in each arm.
Time frame: Up to 2 years
Accuracy of tissue of origin prediction
The proportion of diagnosed cancers that match the tissue of origin predicted by an abnormal (positive) MCD test, for each screening episode.
Time frame: Up to 2 years
Complications related to diagnostic evaluation of an abnormal MCD test result
Adverse events occurring in participants undergoing a diagnostic workup following receipt of an abnormal MCD test result.
Time frame: Up to 1 year
Anxiety and Cancer Worry Questionnaire
Participant anxiety will be assessed with the Patient Reported Outcomes Measurement Information System instrument. Cancer-related worry will be assessed using the Lehrman Cancer Worry Scale.
Time frame: Up to 2 years
Sensitivity of clinical diagnostic performance of each MCD assay
Sensitivity will be estimated for each MCD assay. These sensitivities will also be calculated by early- versus late-stage, and for MCD test-targeted cancers and all cancers.
Time frame: Up to 2 years
Specificity of each MCD assay
Specificity will be estimated for each MCD assay.
Time frame: 1 year
Test positive rates
The proportion of abnormal MCD tests at each screening episode, and the proportion of participants with at least one abnormal test.
Time frame: Up to 2 years
False positives
The number of participants with an abnormal MCD test and no cancer diagnosis.
Time frame: Up to 2 years
(Targeted cancer) Positive predictive value (PPV)
The proportion of abnormal MCD tests that result in diagnosis of one of the MCD test-targeted cancers among participants with at least one abnormal test, for each screening episode.
Time frame: Up to 2 years
(All cancer) PPV
The proportion of abnormal MCD tests that result in diagnosis of any cancer among participants with at least one abnormal test, for each screening episode.
Time frame: Up to 2 years
Interval cancers
The number of MCD test-targeted cancer cases diagnosed within 12 months of a normal MCD test result among participants who received an MCD test, for each screening episode.
Time frame: 1 year
Detected cancers
The number of cancer cases diagnosed within a 12-month follow-up period of an abnormal test result among participants who received an MCD test, for each screening episode.
Time frame: 1 year
(Targeted cancer) Negative predictive value
The proportion of normal MCD tests that did not result in diagnosis of one of the MCD test-targeted cancers among participants with a normal test, for each screening episode.
Time frame: 1 year
Cancer stage
The stage that a cancer was diagnosed (Surveillance, Epidemiology, and End Results \[SEER\]).
Time frame: Up to 12 years
Early and late stages cancer diagnosis
Counts of early and late-stage cancers by arm, separately for each cancer type. Early stage is defined as in situ or localized (SEER). Late stage is defined as regional or distant stage (SEER).
Time frame: Up to 12 years
Targeted cancer-specific mortality of each MCD assay
The fraction of MCD-targeted cancers diagnosed during trial participation that resulted in death.
Time frame: Up to 12 years
Cancer-specific mortality
The fraction of all cancers diagnosed during trial participation that resulted in death.
Time frame: Up to 12 years
All-cause mortality
The probability of participant death by any cause during trial participation, by arm.
Time frame: Up to 12 years
Estimated costs associated with MCD testing minus estimated costs associated with standard of care screening
Will estimate average screening costs associated with MCD testing.
Time frame: Up to 12 years
Participant out of pocket costs
Direct non-medical participant costs; for example, transportation costs, travel time and distance, accommodation costs, childcare or elder-care costs will be elicited through an adapted version of the Costs for Patients Questionnaire. Direct medical care costs paid by participants (e.g., copays, deductible and uncovered medical bills) will be estimated using Medicare reimbursement and coinsurance rates for services received (Medicare Parts A-D).
Time frame: Up to 2 years
Participant work loss
Participant and caregiver time spent away from work will be estimated using an adapted version of the Productivity Cost Questionnaire. The dollar value of hours recorded for participant work loss and caregiver time will be estimated using wages from the Bureau of Labor Statistics.
Time frame: Up to 2 years
Proportion of participants who complete the Military Exposure Questionnaire
Will evaluate the proportion of participants who complete the Military Exposure Questionnaire, among those who reported military service.
Time frame: At baseline
Plan to share: Yes — NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Data sharing details ↗ · grants.nih.gov
Started Jun 2025 (actual). Primary completion is estimated for Jan 2029, 43 months after the start.
Of 237 non-industry interventional studies with no phase under Urinary Bladder Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 69. This study's planned 43 months is close to that.
Counting every sponsor, half of 246 studies reached it within 38 months; a quarter within 18 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Cancer Institute (NCI) →